Lipid management in Europe the SANTORINI study
Kausik Ray
May 21, 2023 | 91th EAS Congress 2023, Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk
TG vs apo B reduction
Brian Ference
May 21, 2023 | Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?, 91th EAS Congress 2023
Panel Discussion: Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk
Kausik Ray, Lale Tokgözoğlu, Luis Masana, Stephen Nicholls
May 21, 2023 | 91th EAS Congress 2023, Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk
Bempedoic acid in clinical practice updates from the MILOS study
May 21, 2023 | 91th EAS Congress 2023, Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk
Combination lipid-modifying therapy in high- and very-high-risk patients
Luis Masana
May 21, 2023 | 91th EAS Congress 2023, Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk
Novel add-on therapeutic options for LDL-C management
Stephen Nicholls
May 21, 2023 | 91th EAS Congress 2023, Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk
Modern approach to dyslipidemia
Peter Libby
May 22, 2023 | 91th EAS Congress 2023, Integrating the many players of cardiovascular risk
Panel Discussion: Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?
Kausik Ray, Lale Tokgözoğlu, Brian Ference, Alberto Zambon, Chris Packard
May 21, 2023 | 91th EAS Congress 2023, Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?
EPA Mechanism(s) of action
Chris Packard
May 21, 2023 | 91th EAS Congress 2023, Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?
FIBRATES The PROMINENT trial
Kausik Ray
May 21, 2023 | 91th EAS Congress 2023, Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?